Global Alzheimer's Disease Therapeutics and Diagnostics Sales Market Report 2022

Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer's disease. One in nine people aged 65 and above has Alzheimer's disease. By 2050, the number of people aged 65 and above affected with Alzheimer's disease is expected to nearly triple, from 5.2 million to an expected 13.8 million, excluding the development of medical advances to avert or cure the disease. The mortality rates due to Alzheimer’s disease are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased 14%, 23% and 11%, respectively, while deaths from AD increased 71% in the U.S. Similarly, According to Alzheimer’s disease International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increasing in the demand for Alzheimer’s therapeutics and diagnostics worldwide.

Population aging across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers. However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand.

Market Analysis and Insights: Global Alzheimer's Disease Therapeutics and Diagnostics Market

Due to the COVID-19 pandemic, the global Alzheimer's Disease Therapeutics and Diagnostics market size is estimated to be worth US$ 4799.8 million in 2021 and is forecast to a readjusted size of US$ 4799.8 million by 2028 with a CAGR of 4.0% during the review period.

Fully considering the economic change by this health crisis, by Type accounting for % of the Alzheimer's Disease Therapeutics and Diagnostics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period.

While by Type segment is altered to an % CAGR throughout this forecast period.

The United States Alzheimer's Disease Therapeutics and Diagnostics market is estimated at US$ million in 2021, while China is forecast to reach US$ million by 2028. The proportion of the United States is % in 2021, while Chinese percentage is %, and it is predicted that China’s share will reach % in 2028, trailing a CAGR of % through the analysis period.

The global key manufacturers of Alzheimer's Disease Therapeutics and Diagnostics include Namenda, Aricept, Exelon, Solanezumab, Gantenerumab, Verubecestat, Pfizer, Eisai and Actavis, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

In United States, in terms of revenue, in 2021, the top three players hold a share about %, while in China, top three players hold a share nearly %.

Global Alzheimer's Disease Therapeutics and Diagnostics Scope and Market Size

The global Alzheimer's Disease Therapeutics and Diagnostics market is segmented by company, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Alzheimer's Disease Therapeutics and Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

Biomarkers

Cholinesterase inhibitors

NMDA receptor antagonists

Brain imaging

Blood tests

Drugs Market

Diagnostics Market

United States

Europe

China

Japan

Southeast Asia

India

Other Regions

Namenda

Aricept

Exelon

Solanezumab

Gantenerumab

Verubecestat

Pfizer

Eisai

Actavis

Lundbeck

Daiichi Sankyo

Novartis

TauRx

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2017 VS 2021VS 2028)

1.2.2 Biomarkers

1.2.3 Cholinesterase inhibitors

1.2.4 NMDA receptor antagonists

1.2.5 Brain imaging

1.2.6 Blood tests

1.3 Market by Application

1.3.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2017 VS 2021 VS 2028)

1.3.2 Drugs Market

1.3.3 Diagnostics Market

1.4 Study Objectives

1.5 Years Considered

2.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Perspective (2017-2028)

2.2 Global Alzheimer's Disease Therapeutics and Diagnostics Market Size by Region: 2017 VS 2021 VS 2028

2.3 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Region (2017-2022)

2.4 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Forecast by Region (2023-2028)

2.5 Geographic Market Analysis: Market Facts & Figures

2.5.1 United States Alzheimer's Disease Therapeutics and Diagnostics Estimates and Projections (2017-2028)

2.5.2 Europe Alzheimer's Disease Therapeutics and Diagnostics Estimates and Projections (2017-2028)

2.5.3 China Alzheimer's Disease Therapeutics and Diagnostics Estimates and Projections (2017-2028)

2.5.4 Japan Alzheimer's Disease Therapeutics and Diagnostics Estimates and Projections (2017-2028)

2.5.5 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Estimates and Projections (2017-2028)

2.5.6 India Alzheimer's Disease Therapeutics and Diagnostics Estimates and Projections (2017-2028)

3.1 Global Top Alzheimer's Disease Therapeutics and Diagnostics Players by Revenue (2017-2022)

3.1.1 Global Top Alzheimer's Disease Therapeutics and Diagnostics Players by Revenue (2017-2022)

3.1.2 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Players (2017-2022)

3.2 Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.3 Players Covered: Ranking by Alzheimer's Disease Therapeutics and Diagnostics Revenue

3.4 Global Alzheimer's Disease Therapeutics and Diagnostics Market Concentration Ratio

3.4.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Alzheimer's Disease Therapeutics and Diagnostics Revenue in 2021

3.5 Alzheimer's Disease Therapeutics and Diagnostics Key Players Head office and Area Served

3.6 Key Players Alzheimer's Disease Therapeutics and Diagnostics Product Solution and Service

3.7 Date of Enter into Alzheimer's Disease Therapeutics and Diagnostics Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Alzheimer's Disease Therapeutics and Diagnostics Historic Market Size by Type (2017-2022)

4.2 Global Alzheimer's Disease Therapeutics and Diagnostics Forecasted Market Size by Type (2023-2028)

5.1 Global Alzheimer's Disease Therapeutics and Diagnostics Historic Market Size by Application (2017-2022)

5.2 Global Alzheimer's Disease Therapeutics and Diagnostics Forecasted Market Size by Application (2023-2028)

6.1 United States Alzheimer's Disease Therapeutics and Diagnostics Revenue by Company (2017-2022)

6.2 United States Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type

6.2.1 United States Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2017-2022)

6.2.2 United States Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2023-2028)

6.2.3 United States Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2017-2028)

6.3 United States Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application

6.3.1 United States Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2017-2022)

6.3.2 United States Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2023-2028)

6.3.3 United States Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2017-2028)

7.1 Europe Alzheimer's Disease Therapeutics and Diagnostics Revenue by Company (2017-2022)

7.2 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type

7.2.1 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2017-2022)

7.2.2 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2023-2028)

7.2.3 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2017-2028)

7.3 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application

7.3.1 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2017-2022)

7.3.2 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2023-2028)

7.3.3 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2017-2028)

8.1 China Alzheimer's Disease Therapeutics and Diagnostics Revenue by Company (2017-2022)

8.2 China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type

8.2.1 China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2017-2022)

8.2.2 China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2023-2028)

8.2.3 China Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2017-2028)

8.3 China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application

8.3.1 China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2017-2022)

8.3.2 China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2023-2028)

8.3.3 China Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2017-2028)

9.1 Japan Alzheimer's Disease Therapeutics and Diagnostics Revenue by Company (2017-2022)

9.2 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type

9.2.1 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2017-2022)

9.2.2 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2023-2028)

9.2.3 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2017-2028)

9.3 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application

9.3.1 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2017-2022)

9.3.2 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2023-2028)

9.3.3 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2017-2028)

10.1 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Revenue by Company (2017-2022)

10.2 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type

10.2.1 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2017-2022)

10.2.2 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2023-2028)

10.2.3 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2017-2028)

10.3 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application

10.3.1 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2017-2022)

10.3.2 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2023-2028)

10.3.3 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2017-2028)

11.1 India Alzheimer's Disease Therapeutics and Diagnostics Revenue by Company (2017-2022)

11.2 India Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type

11.2.1 India Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2017-2022)

11.2.2 India Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2023-2028)

11.2.3 India Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2017-2028)

11.3 India Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application

11.3.1 India Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2017-2022)

11.3.2 India Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2023-2028)

11.3.3 India Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2017-2028)

12.1 Namenda

12.1.1 Namenda Company Details

12.1.2 Namenda Business Overview

12.1.3 Namenda Alzheimer's Disease Therapeutics and Diagnostics Introduction

12.1.4 Namenda Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

12.1.5 Namenda Recent Development

12.2 Aricept

12.2.1 Aricept Company Details

12.2.2 Aricept Business Overview

12.2.3 Aricept Alzheimer's Disease Therapeutics and Diagnostics Introduction

12.2.4 Aricept Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

12.2.5 Aricept Recent Development

12.3 Exelon

12.3.1 Exelon Company Details

12.3.2 Exelon Business Overview

12.3.3 Exelon Alzheimer's Disease Therapeutics and Diagnostics Introduction

12.3.4 Exelon Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

12.3.5 Exelon Recent Development

12.4 Solanezumab

12.4.1 Solanezumab Company Details

12.4.2 Solanezumab Business Overview

12.4.3 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Introduction

12.4.4 Solanezumab Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

12.4.5 Solanezumab Recent Development

12.5 Gantenerumab

12.5.1 Gantenerumab Company Details

12.5.2 Gantenerumab Business Overview

12.5.3 Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Introduction

12.5.4 Gantenerumab Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

12.5.5 Gantenerumab Recent Development

12.6 Verubecestat

12.6.1 Verubecestat Company Details

12.6.2 Verubecestat Business Overview

12.6.3 Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Introduction

12.6.4 Verubecestat Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

12.6.5 Verubecestat Recent Development

12.7 Pfizer

12.7.1 Pfizer Company Details

12.7.2 Pfizer Business Overview

12.7.3 Pfizer Alzheimer's Disease Therapeutics and Diagnostics Introduction

12.7.4 Pfizer Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

12.7.5 Pfizer Recent Development

12.8 Eisai

12.8.1 Eisai Company Details

12.8.2 Eisai Business Overview

12.8.3 Eisai Alzheimer's Disease Therapeutics and Diagnostics Introduction

12.8.4 Eisai Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

12.8.5 Eisai Recent Development

12.9 Actavis

12.9.1 Actavis Company Details

12.9.2 Actavis Business Overview

12.9.3 Actavis Alzheimer's Disease Therapeutics and Diagnostics Introduction

12.9.4 Actavis Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

12.9.5 Actavis Recent Development

12.10 Lundbeck

12.10.1 Lundbeck Company Details

12.10.2 Lundbeck Business Overview

12.10.3 Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Introduction

12.10.4 Lundbeck Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

12.10.5 Lundbeck Recent Development

12.11 Daiichi Sankyo

12.11.1 Daiichi Sankyo Company Details

12.11.2 Daiichi Sankyo Business Overview

12.11.3 Daiichi Sankyo Alzheimer's Disease Therapeutics and Diagnostics Introduction

12.11.4 Daiichi Sankyo Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

12.11.5 Daiichi Sankyo Recent Development

12.12 Novartis

12.12.1 Novartis Company Details

12.12.2 Novartis Business Overview

12.12.3 Novartis Alzheimer's Disease Therapeutics and Diagnostics Introduction

12.12.4 Novartis Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

12.12.5 Novartis Recent Development

12.13 TauRx

12.13.1 TauRx Company Details

12.13.2 TauRx Business Overview

12.13.3 TauRx Alzheimer's Disease Therapeutics and Diagnostics Introduction

12.13.4 TauRx Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

12.13.5 TauRx Recent Development

13.1 Alzheimer's Disease Therapeutics and Diagnostics Industry Trends

13.2 Alzheimer's Disease Therapeutics and Diagnostics Market Drivers

13.3 Alzheimer's Disease Therapeutics and Diagnostics Market Challenges

13.4 Alzheimer's Disease Therapeutics and Diagnostics Market Restraints

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Author List

15.3 Disclaimer

List of Tables

    Table 1. Global Alzheimer's Disease Therapeutics and Diagnostics Market Size Growth Rate by Type (US$ Million): (2017 VS 2021 VS 2028)

    Table 2. Major Players of Biomarkers

    Table 3. Major Players of Cholinesterase inhibitors

    Table 4. Key Players of NMDA receptor antagonists

    Table 5. Key Players of Brain imaging

    Table 6. Key Players of Blood tests

    Table 7. Global Alzheimer's Disease Therapeutics and Diagnostics Market Size Growth by Application (2017 VS 2021 VS 2028)

    Table 8. Global Alzheimer's Disease Therapeutics and Diagnostics Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028

    Table 9. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue (US$ Million) Market Share by Region (2017-2022))

    Table 10. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Share by Region (2017-2022)

    Table 11. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue (US$ Million) Forecast by Region (2023-2028)

    Table 12. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Share Forecast by Region (2023-2028)

    Table 13. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue by Players (2017-2022) & (US$ Million)

    Table 14. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Share by Players (2017-2022)

    Table 15. Global Alzheimer's Disease Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alzheimer's Disease Therapeutics and Diagnostics as of 2021)

    Table 16. Ranking of Global Top Alzheimer's Disease Therapeutics and Diagnostics Companies by Revenue (US$ Million) in 2021

    Table 17. Global 5 Largest Players Market Share by Alzheimer's Disease Therapeutics and Diagnostics Revenue (CR5 and HHI) & (2017-2022)

    Table 18. Key Players Headquarters and Area Served

    Table 19. Key Players Alzheimer's Disease Therapeutics and Diagnostics Product Solution and Service

    Table 20. Date of Enter into Alzheimer's Disease Therapeutics and Diagnostics Market

    Table 21. Mergers & Acquisitions, Expansion Plans

    Table 22. Global Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2017-2022) & (US$ Million)

    Table 23. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Type (2017-2022)

    Table 24. Global Alzheimer's Disease Therapeutics and Diagnostics Forecasted Market Size by Type (2023-2028) & (US$ Million)

    Table 25. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Type (2023-2028)

    Table 26. Global Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2017-2022) & (US$ Million)

    Table 27. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Application (2017-2022)

    Table 28. Global Alzheimer's Disease Therapeutics and Diagnostics Forecasted Market Size by Application (2023-2028) & (US$ Million)

    Table 29. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Application (2023-2028)

    Table 30. United States Alzheimer's Disease Therapeutics and Diagnostics Revenue by Company (2017-2022) & (US$ Million)

    Table 31. United States Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Company (2017-2022)

    Table 32. United States Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2017-2022) & (K Units)

    Table 33. United States Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2023-2028) & (K Units)

    Table 34. United States Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2017-2022) & (K Units)

    Table 35. United States Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2023-2028) & (K Units)

    Table 36. Europe Alzheimer's Disease Therapeutics and Diagnostics Revenue by Company (2017-2022) & (US$ Million)

    Table 37. Europe Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Company (2017-2022)

    Table 38. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2017-2022) & (US$ Million)

    Table 39. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2023-2028) & (US$ Million)

    Table 40. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2017-2022) & (US$ Million)

    Table 41. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2023-2028) & (US$ Million)

    Table 42. China Alzheimer's Disease Therapeutics and Diagnostics Revenue by Company (2017-2022) & (US$ Million)

    Table 43. China Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Company (2017-2022)

    Table 44. China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2017-2022) & (US$ Million)

    Table 45. China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2023-2028) & (US$ Million)

    Table 46. China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2017-2022) & (US$ Million)

    Table 47. China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2023-2028) & (US$ Million)

    Table 48. Japan Alzheimer's Disease Therapeutics and Diagnostics Revenue by Company (2017-2022) & (US$ Million)

    Table 49. Japan Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Company (2017-2022)

    Table 50. Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2017-2022) & (US$ Million)

    Table 51. Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2023-2028) & (US$ Million)

    Table 52. Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2017-2022) & (US$ Million)

    Table 53. Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2023-2028) & (US$ Million)

    Table 54. Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Revenue by Company (2017-2022) & (US$ Million)

    Table 55. Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Company (2017-2022)

    Table 56. Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2017-2022) & (US$ Million)

    Table 57. Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2023-2028) & (US$ Million)

    Table 58. Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2017-2022) & (US$ Million)

    Table 59. Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2023-2028) & (US$ Million)

    Table 60. India Alzheimer's Disease Therapeutics and Diagnostics Revenue by Company (2017-2022) & (US$ Million)

    Table 61. India Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Company (2017-2022)

    Table 62. India Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2017-2022) & (US$ Million)

    Table 63. India Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2023-2028) & (US$ Million)

    Table 64. India Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2017-2022) & (US$ Million)

    Table 65. India Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2023-2028) & (US$ Million)

    Table 66. Namenda Company Details

    Table 67. Namenda Description and Business Overview

    Table 68. Namenda Alzheimer's Disease Therapeutics and Diagnostics Product

    Table 69. Namenda Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022) & (US$ Million)

    Table 70. Namenda Recent Development

    Table 71. Aricept Company Details

    Table 72. Aricept Description and Business Overview

    Table 73. Aricept Alzheimer's Disease Therapeutics and Diagnostics Product

    Table 74. Aricept Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022) & (US$ Million)

    Table 75. Aricept Recent Development

    Table 76. Exelon Company Details

    Table 77. Exelon Description and Business Overview

    Table 78. Exelon Alzheimer's Disease Therapeutics and Diagnostics Product

    Table 79. Exelon Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022) & (US$ Million)

    Table 80. Exelon Recent Development

    Table 81. Solanezumab Company Details

    Table 82. Solanezumab Description and Business Overview

    Table 83. Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Product

    Table 84. Solanezumab Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022) & (US$ Million)

    Table 85. Solanezumab Recent Development

    Table 86. Gantenerumab Company Details

    Table 87. Gantenerumab Description and Business Overview

    Table 88. Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Product

    Table 89. Gantenerumab Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022) & (US$ Million)

    Table 90. Gantenerumab Recent Development

    Table 91. Verubecestat Company Details

    Table 92. Verubecestat Description and Business Overview

    Table 93. Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Product

    Table 94. Verubecestat Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022) & (US$ Million)

    Table 95. Verubecestat Recent Development

    Table 96. Pfizer Company Details

    Table 97. Pfizer Description and Business Overview

    Table 98. Pfizer Alzheimer's Disease Therapeutics and Diagnostics Product

    Table 99. Pfizer Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022) & (US$ Million)

    Table 100. Pfizer Recent Development

    Table 101. Eisai Company Details

    Table 102. Eisai Alzheimer's Disease Therapeutics and Diagnostics Product

    Table 103. Eisai Description and Business Overview

    Table 104. Eisai Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022) & (US$ Million)

    Table 105. Eisai Recent Development

    Table 106. Actavis Company Details

    Table 107. Actavis Alzheimer's Disease Therapeutics and Diagnostics Product

    Table 108. Actavis Description and Business Overview

    Table 109. Actavis Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022) & (US$ Million)

    Table 110. Actavis Recent Development

    Table 111. Lundbeck Company Details

    Table 112. Lundbeck Description and Business Overview

    Table 113. Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Product

    Table 114. Lundbeck Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022) & (US$ Million)

    Table 115. Lundbeck Recent Development

    Table 116. Daiichi Sankyo Company Details

    Table 117. Daiichi Sankyo Description and Business Overview

    Table 118. Daiichi Sankyo Alzheimer's Disease Therapeutics and Diagnostics Product

    Table 119. Daiichi Sankyo Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022) & (US$ Million)

    Table 120. Daiichi Sankyo Recent Development

    Table 121. Novartis Company Details

    Table 122. Novartis Description and Business Overview

    Table 123. Novartis Alzheimer's Disease Therapeutics and Diagnostics Product

    Table 124. Novartis Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022) & (US$ Million)

    Table 125. Novartis Recent Development

    Table 126. TauRx Company Details

    Table 127. TauRx Description and Business Overview

    Table 128. TauRx Alzheimer's Disease Therapeutics and Diagnostics Product

    Table 129. TauRx Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022) & (US$ Million)

    Table 130. TauRx Recent Development

    Table 131. Alzheimer's Disease Therapeutics and Diagnostics Market Trends

    Table 132. Alzheimer's Disease Therapeutics and Diagnostics Market Drivers

    Table 133. Alzheimer's Disease Therapeutics and Diagnostics Market Challenges

    Table 134. Alzheimer's Disease Therapeutics and Diagnostics Market Restraints

    Table 135. Research Programs/Design for This Report

    Table 136. Key Data Information from Secondary Sources

    Table 137. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type: 2021 VS 2028

    Figure 2. Biomarkers Features

    Figure 3. Cholinesterase inhibitors Features

    Figure 4. NMDA receptor antagonists Features

    Figure 5. Brain imaging Features

    Figure 6. Blood tests Features

    Figure 7. Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application: 2021 VS 2028

    Figure 8. Drugs Market Case Studies

    Figure 9. Diagnostics Market Case Studies

    Figure 10. Alzheimer's Disease Therapeutics and Diagnostics Report Years Considered

    Figure 11. Global Alzheimer's Disease Therapeutics and Diagnostics Market Size (US$ Million), Year-over-Year: 2017-2028

    Figure 12. Global Alzheimer's Disease Therapeutics and Diagnostics Market Size, (US$ Million), 2017 VS 2021 VS 2028

    Figure 13. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Region: 2017 VS 2021

    Figure 14. United States Alzheimer's Disease Therapeutics and Diagnostics Revenue (Million USD) Growth Rate (2017-2028)

    Figure 15. Europe Alzheimer's Disease Therapeutics and Diagnostics Revenue (Million USD) Growth Rate (2017-2028)

    Figure 16. China Alzheimer's Disease Therapeutics and Diagnostics Revenue (Million USD) Growth Rate (2017-2028)

    Figure 17. Japan Alzheimer's Disease Therapeutics and Diagnostics Revenue (Million USD) Growth Rate (2017-2028)

    Figure 18. Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Revenue (Million USD) Growth Rate (2017-2028)

    Figure 19. India Alzheimer's Disease Therapeutics and Diagnostics Revenue (Million USD) Growth Rate (2017-2028)

    Figure 20. Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Players in 2021

    Figure 21. Global Top Alzheimer's Disease Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alzheimer's Disease Therapeutics and Diagnostics as of 2021)

    Figure 22. The Top 10 and 5 Players Market Share by Alzheimer's Disease Therapeutics and Diagnostics Revenue in 2021

    Figure 23. United States Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2017-2028)

    Figure 24. United States Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2017-2028)

    Figure 25. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2017-2028)

    Figure 26. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2017-2028)

    Figure 27. China Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2017-2028)

    Figure 28. China Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2017-2028)

    Figure 29. Japan Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2017-2028)

    Figure 30. Japan Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2017-2028)

    Figure 31. Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2017-2028)

    Figure 32. Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2017-2028)

    Figure 33. India Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2017-2028)

    Figure 34. India Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2017-2028)

    Figure 35. Namenda Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

    Figure 36. Aricept Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

    Figure 37. Exelon Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

    Figure 38. Solanezumab Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

    Figure 39. Gantenerumab Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

    Figure 40. Verubecestat Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

    Figure 41. Pfizer Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

    Figure 42. Eisai Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

    Figure 43. Actavis Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

    Figure 44. Lundbeck Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

    Figure 45. Daiichi Sankyo Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

    Figure 46. Novartis Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

    Figure 47. TauRx Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2017-2022)

    Figure 48. Bottom-up and Top-down Approaches for This Report

    Figure 49. Data Triangulation

    Figure 50. Key Executives Interviewed